Age-related macular degeneration: a guide for the primary care physician.
Age-related macular degeneration (AMD) is the leading cause of visual loss in Americans over the age of 50 years. AMD often results in profound disability due to the disease destroying the macula, the part of the retina responsible for central visual acuity and color vision. Risk factors for AMD include age greater than 50, female gender, Caucasian race, cigarette smoking, and family history of AMD. African Americans and other racial or ethnic groups can be affected by AMD. Although there is no cure for AMD, early diagnosis and treatment may slow disease progression and minimize irreversible visual dysfunction. Individuals suffering from central vision loss from AMD often retain peripheral vision. These affected individuals can benefit from low vision therapy, visual rehabilitation, or both to maintain or enhance activities of daily living.
Hazin
Ribhi
R
University of Nebraska Medical Center, Department of Genetics, Cell Biology, and Ophthalmology and Visual Sciences, Omaha, NE 68198, USA. hazin@fas.harvard.edu
Freeman
P David
PD
Kahook
Malik Y
MY
D000367:Age Factors; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005006:Ethnicity / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D008268:Macular Degeneration / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D013508:Ophthalmologic Surgical Procedures; D011320:Primary Health Care / Q000379:methods*; D000069579:Ranibizumab; D012307:Risk Factors; D012737:Sex Factors; D016896:Treatment Outcome; D014481:United States; D014815:Vitamins / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014815:Vitamins; D000068258:Bevacizumab; D000069579:Ranibizumab